TY - JOUR
T1 - 5-[123I]iodo-A-85380
T2 - Assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects
AU - Ueda, Masashi
AU - Iida, Yasuhiko
AU - Mukai, Takahiro
AU - Mamede, Marcelo
AU - Ishizu, Koichi
AU - Ogawa, Mikako
AU - Magata, Yasuhiro
AU - Konishi, Junji
AU - Saji, Hideo
N1 - Funding Information:
This work was supported in part by a grant-in-aid for Scientific Research from the Ministry of Education, Science and Technology of Japan, a grant from 21st Century COE program "Knowledge Information Infrastructure for Genome Science" and a grant from the Smoking Research Foundation. The authors thank Nihon Medi-Physics Co. Ltd. for providing sodium \[123I\]iodine.
PY - 2004/6
Y1 - 2004/6
N2 - Recently, 5-[123I]iodo-3-(2(S)-azetidinylmethoxy)pyridine ([123I]5IA) was developed as a ligand for imaging the nicotinic acetylcholine receptor (nAChR) in human brain using single photon emission computed tomography (SPECT). In the present study, the toxicity and radiation absorbed dose of [123I]5IA were investigated. Behavior and physiological parameters were examined in mice and rats after administration of 5IA. There were no changes in these parameters in animals administered 1 μg/kg of 5IA or less, indicating that the no observed effect level (NOEL) of 5IA was 1 μg/kg. [123I]5IA was then administered to healthy human subjects and serial whole-body images were acquired over 24 hr. Initially, high levels of radioactivity were observed in the liver and urinary bladder and moderate levels in the lungs, kidneys, and brain. Whole brain activity at 1 hr was 4.6 ± 0.4% of the injected dose and this value gradually decreased with time. The majority (∼75%) of the radioactivity was excreted in urine within 24 hr, and less than 1% remained in all organs tested. The biological half-life of [123I]5IA averaged 7.2 ± 4.0 hr. Based on the biodistribution data, radiation absorbed doses were estimated using MIRDOSE 3.1 software with the dynamic bladder model and the ICRP gastrointestinal (GI) tract model. Consequently, the effective dose equivalent was estimated to be 30 ± 1.4 μSv/MBq, which is an acceptable radiation burden. Having determined the safety of this compound, we performed SPECT imaging in a healthy human subject using 171 MBq of [123I]5IA. SPECT images clearly revealed a cerebral distribution of radioactivity that was consistent with the known distribution of central nAChRs in humans. These results suggest that [123I]5IA is a promising ligand for imaging nAChRs in humans, with an acceptable dosimetry and pharmacological safety at the dose required for adequate SPECT imaging.
AB - Recently, 5-[123I]iodo-3-(2(S)-azetidinylmethoxy)pyridine ([123I]5IA) was developed as a ligand for imaging the nicotinic acetylcholine receptor (nAChR) in human brain using single photon emission computed tomography (SPECT). In the present study, the toxicity and radiation absorbed dose of [123I]5IA were investigated. Behavior and physiological parameters were examined in mice and rats after administration of 5IA. There were no changes in these parameters in animals administered 1 μg/kg of 5IA or less, indicating that the no observed effect level (NOEL) of 5IA was 1 μg/kg. [123I]5IA was then administered to healthy human subjects and serial whole-body images were acquired over 24 hr. Initially, high levels of radioactivity were observed in the liver and urinary bladder and moderate levels in the lungs, kidneys, and brain. Whole brain activity at 1 hr was 4.6 ± 0.4% of the injected dose and this value gradually decreased with time. The majority (∼75%) of the radioactivity was excreted in urine within 24 hr, and less than 1% remained in all organs tested. The biological half-life of [123I]5IA averaged 7.2 ± 4.0 hr. Based on the biodistribution data, radiation absorbed doses were estimated using MIRDOSE 3.1 software with the dynamic bladder model and the ICRP gastrointestinal (GI) tract model. Consequently, the effective dose equivalent was estimated to be 30 ± 1.4 μSv/MBq, which is an acceptable radiation burden. Having determined the safety of this compound, we performed SPECT imaging in a healthy human subject using 171 MBq of [123I]5IA. SPECT images clearly revealed a cerebral distribution of radioactivity that was consistent with the known distribution of central nAChRs in humans. These results suggest that [123I]5IA is a promising ligand for imaging nAChRs in humans, with an acceptable dosimetry and pharmacological safety at the dose required for adequate SPECT imaging.
KW - Nicotinic acetylcholine receptor
KW - Pharmacological effects
KW - Radiation dosimetry
KW - Single photon emission computed tomography
UR - http://www.scopus.com/inward/record.url?scp=4143054599&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4143054599&partnerID=8YFLogxK
U2 - 10.1007/BF02984473
DO - 10.1007/BF02984473
M3 - Article
C2 - 15359928
AN - SCOPUS:4143054599
SN - 0914-7187
VL - 18
SP - 337
EP - 344
JO - Annals of nuclear medicine
JF - Annals of nuclear medicine
IS - 4
ER -
